Jim Cramer's Mad Dash: Regeneron to $400; Conn's a No-Touch

NEW YORK (TheStreet) -- On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, was very excited about Regeneron's (REGN) new cholesterol drug, Alirocumab. 

The company's anti-cholesterol drug is an alternative to statin and reduces the risk of strokes. Regeneron is partnered with Sanofi (SNY) for Alirocumab. 

Read More: Dollar General Offers Major Antitrust Concessions as It Lifts Bid for Family Dollar

The stock is breaking out, Cramer said, adding that Credit Suisse suggests it can go to $400 per share. 

"It's a very big win for Regeneron. It could be a multi-billion market," he said. 

Turning to Conn's (CONN) , Cramer noted that the stock is plummeting -- down over 30%. Management expressed concern that customers would not be paying Conn's the money it is owed. 

Investors want exposure to domestic retailers to protect themselves from geopolitical risks, Cramer said, but not all domestic retailers are created equal. 

He concluded that he is not a buyer of Conn's following the selloff, because a lot of investors still want to get out of the stock. 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

Read More: 10 Most Affordable Cars Of 2014

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Action Was Under the Surface in Monday's Market

Stock Futures Move Lower Ahead of Loaded Back-Half to the Week

5 Things You Must Know Before the Market Opens Tuesday

Week Ahead: You Won't Hear Much From the Fed Before the Central Bank's Rates Meeting